Company
Cardurion Pharmaceuticals
Advancing groundbreaking clinical programs to address the continuing unmet needs of patients with cardiovascular disease.
Also known as Cardurion Pharmaceuticals, Inc.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Legal name
- Cardurion Pharmaceuticals, Inc.
- cardurion.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Cardurion is a clinical-stage biotechnology company discovering and developing new therapeutic approaches to address the leading cause of death worldwide – cardiovascular disease.
Funding snapshot
- Total raised
- $560MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Series B, $260M2024-07-16
Funding rounds
- Series B
- $260M2024-07-16, Company stated
- Round, 2024
- $260M2024-07-10, SEC form D sold, 19 investors
- Round, 2022
- $17.5M2022-12-16, SEC form D sold, 2 investors
- Round, 2021
- $300M2021-10-27, Company stated
- Round, 2021
- $128M2021-10-19, SEC form D sold, 2 investors
- Round, 2019
- $10M2019-11-05, SEC form D sold, 2 investors
- Round, 2017
- $15.7M2017-03-20, SEC form D sold, 1 investor
Products
- Web
- CRD-733
- Web
- Tovinontrine (CRD-750)
Loading relationship preview